Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.

A 51-year-old on TRT plans to use steroids and is concerned about hair loss, considering topical treatments like Hair Rescue with RU58841 and finasteride, along with Nioxin shampoo. They are cautious about using oral DHT blockers due to potential interactions with steroids like Tren and Anavar.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

Dr. Gabel doesn't use Verteporfin because it's not FDA approved. The user is getting FUT and wants to minimize scarring and maximize hair regrowth.

Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.

The user had a hair transplant of 3400 grafts, primarily focusing on the hairline, and is happy with the results four months post-surgery. They used topical minoxidil, oral minoxidil, finasteride, and topical dutasteride, along with microneedling and Nizoral, and the procedure cost around $12,000.

The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.

A female with male-pattern hair loss (AGA) is seeking help after unsuccessful treatments with spironolactone and supplements, and is considering oral minoxidil and finasteride despite concerns about medication side effects. She has ruled out hormonal birth control and PRP/PRFM, and is looking into further medical advice due to abnormal lab results.

A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.

The conversation is about whether doctors are offering hair transplants using verteporfin. Dr. Bargouthi in Jordan and Dr. Bloxham in New York are currently conducting trials on it.

Oral minoxidil was ineffective for OP, causing hair loss and unwanted body hair, while topical minoxidil showed significant regrowth. OP is switching to topical minoxidil with glycerin due to scalp issues with propylene glycol.

OP shared an 8-month update on hair transplant results, using Dutasteride, oral Minoxidil, and Biotin. OP also discussed a simple skincare routine with Cerave products and sunscreen.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation discusses the anticipation for updates on GT20029, a potential hair loss treatment. Users also mention using Minoxidil, finasteride, and RU58841.

OP is planning a hair transplant but has gyno surgery scheduled next month. It's recommended to wait 4-6 weeks after the gyno surgery before proceeding with the hair transplant.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

The post discusses a hair loss treatment regime using Nizoral, a laser helmet, dermaroller, bentonite clay mask with essential oils, and ketoconazole shampoo. The user avoids finasteride and minoxidil due to concerns about side effects and pet safety.